ClinicalTrials.gg

Program

telikibart

Its studies are mostly in Rhinitis, Allergic, Seasonal · Nasal Polyps · Rhinitis, Allergic · Asthma · Dermatitis, Atopic, led by Chongqing Genrix Biopharmaceutical.

Furthest: phase 3, since Jan 11, 20247 company-led studies, 7 open or runningNext primary completion: May 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Genrix Biopharmaceutical77 open or runningphase 3since Jan 11, 2024May 16, 2023May 15, 2027phase 3 · NCT07199257

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 16, 2023First study: phase 2 study in Chronic Rhinosinusitis with Nasal PolypsFirst studyNCT05873803 · 70 enrolled · China
  2. Aug 15, 2023Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06015243 · 70 planned
  3. Jan 11, 2024Phase 3 study in Dermatitis, AtopicNCT06216392 · 450 planned · China
  4. Mar 11, 2024Phase 2 study in Rhinitis, AllergicNCT06315426 · 240 enrolled · China
  5. Oct 14, 2024Phase 2 study in AsthmaNCT06642961 · 150 planned · China
  6. Aug 13, 2025Phase 3 study in Rhinitis, Allergic, SeasonalNCT07154342 · 150 planned · China
  7. Sep 22, 2025Phase 3 study in Rhinitis, Allergic, SeasonalNCT07199257 · 144 planned · China

Ahead

  1. May 15, 2027Primary completion: phase 3 study in Rhinitis, Allergic, SeasonalNCT07199257

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07199257Rhinitis, Allergic, Seasonal · China3Not yet recruitingMay 15, 2027144
NCT07154342Rhinitis, Allergic, Seasonal · China3RecruitingApr 30, 2026150
NCT06642961Asthma · China2RecruitingMar 31, 2025150
NCT06315426Rhinitis, Allergic · China2Active, not recruitingMay 2025240
NCT06216392Dermatitis, Atopic · China3Not yet recruitingJun 2025450
NCT06015243Chronic Rhinosinusitis With Nasal Polyps2Not yet recruitingDec 30, 202470
NCT05873803Chronic Rhinosinusitis with Nasal Polyps · China2Active, not recruitingOct 30, 202470

How it is read

Names in the registry

  • “GR1802 injection”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.